ArticleExperimental and therapeutic medicine2018
Regulatory role of microRNA-185 in the recovery process after ankle fracture.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The MicroRNAs in the Pathophysiology of Osteoporosis.International journal of molecular sciences · 2024Review
- Post-Transcriptional Regulatory Crosstalk between MicroRNAs and Canonical TGF-β/BMP Signalling Cascades on Osteoblast Lineage: A Comprehensive Review.International journal of molecular sciences · 2023Review
- Mmu-miR-185 depletion promotes osteogenic differentiation and suppresses bone loss in osteoporosis through the Bgn-mediated BMP/Smad pathway.Cell death & disease · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the expression of microRNA (miR)-185 in the bone and blood tissues following ankle fracture, and its regulatory mechanism in the ankle fracture recovery process. In total, 28 patients with ankle fractures were included, including 15 cases receiving surgical treatment within 1-7 days after fracture, and 13 cases receiving surgery within 8-14 days after fracture. Reverse transcription-quantitative polymerase chain reaction was performed to detect the mRNA expression levels. Western blot analysis and ELISA were used to determine the protein expression levels. Bioinformatics analysis and dual-luciferase reporter assay were applied to predict and confirm the upstream regulator of tumor growth factor (TGF)-β1. An MTT assay was performed to assess the cell proliferation. Compared with the 1-7-day surgery group, the mRNA and protein expression levels of TGF-β1 were significantly elevated, while the expression levels of miR-185 were significantly declined in the bone and blood tissues in the 8-14-day surgery group. Bioinformatics analysis and dual-luciferase reporter assay predicted and confirmed that TGF-β1 was the direct target gene of miR-185. Moreover, upregulated expression of miR-185 significantly decreased the protein expression levels of TGF-β1 and reduced the proliferating activity of hFOB1.19 cells. Within two weeks after ankle fracture, the expression levels of TGF-β1 are significantly upregulated in the bone and blood tissues, which may have been associated with the downregulated expression of miR-185. miR-185 may modulate TGF-β1 to regulate the recovery of ankle fracture. These findings may contribute to the understanding of the biological functions and effects of miRNA-185 and TGF-β1 in ankle fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.